Drug Device Combination Market research report, by Product (catheter, antimicrobial applications, advanced wound care products), Application (coronary angioplasty, tachycardia management), End user (hospitals & clinics) – Global Forecast till 2027Market HighlightsFollowing a careful analysis of the latest trends, Market Research Future (MRFR) in its latest report states that the drug device combination market is on track to demonstrate a healthy growth rate of 11.4% during the forecast period (2018-2023).Growth Drivers and Top BarriersDrug device combination allows early diagnosis along with shorter treatment duration in most of the surgical procedures.
The surge in the demand is also the result of various other benefits including minimal pain, improved safety, cost efficiency, high efficacy, speedy recovery, and decreased hospital stay owing to these devices.The growing number of regulatory healthcare authorities defining the strict protocols for premarket authorizations is projected to prompt the manufacturers in getting approvals for their products.
The stringent safety guidelines as well as recommendations by the authorities across the globe are poised to raise the adoption rate of these products in the coming years, stimulating the growth of the overall market.Adverse side effects linked with therapeutics on account of the drug absorption by certain locations within the body are considered to be the catalysts in the growing need for targeted therapy, which is expected to elevate the demand for drug-device combinations in the process.
All these factors are set to fuel the clinical need for incorporating alternatives whose basic core is targeted therapy, which is the same with drug-device combination products.Request Free Sample Copy @ https://www.marketresearchfuture.com/sample_request/6946Market SegmentationThe worldwide drug device combination market has been segmented on the basis of product, application, and end user.In terms of product, the market can be broken down into catheter, advanced wound care products, and others.Application-wise segments in the market are coronary angioplasty, tachycardia management, non-cardiovascular treatments, peripheral arterial disease (pad), bone treatment, antimicrobial applications, wound care, ophthalmic treatment, and others.The end users covered in the report include hospitals & clinics, ambulatory centers, and academic & research organization, and others.Companies ProfiledThe leading participants in the worldwide drug device combination are Abbott Laboratories, AlloSource, Biomet Orthopedics, Inc., Wright Medical Group, Inc., Biotronik, Boston Scientific Corporation, St. Jude Medical Inc, 3M Inc., Covidien Ltd, Biometrix Medical, Stryker Corporation, C.R.
BARD, Zimmer Holding, Inc., Cook Critical Care, Inc., Smith & Nephew Plc, and others.Regional SegmentationThe Americas, Europe, Asia Pacific and the Middle East & Africa are the key regions in the global drug device combination market.The Americas has left other regions in the lurch with the dominant share of the overall market, due to the growing prevalence of cardiovascular diseases coupled with the existence of prominent players based in the region.
Moreover, appropriate reimbursement policies, elevated spending on healthcare, and a well-established healthcare industry in the United States (U.S.) and Canada are identified as the crucial drivers for the drug device combination market in the region.The data experts report that Europe had been at the second position in the global drug device combination market in 2017, with factors like the presence of a highly-developed healthcare infrastructure, surging awareness about the devices and the massive contribution of developed nations in the region backing the market growth.
